Substituted benzopyrans as selective estrogen receptor-beta agonists
US7354951B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 5, 2005 |
| Grant date | Apr 8, 2008 |
| Priority date | — |
| Expiry date | Oct 5, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel benzopyran ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis. Formula (I), wherein G is —O—, —S(O)n, —CF2—, —C(O)—, —CR1H— or —CR2(OH)—; R is halo, (C1-C4)alkyl or R3—(CH2)m—; R1 is F, hydroxyl, cyano, trifluoromethyl, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkylcarbonyloxy or benzyl; R2 is trifluoromethyl or (C1-C4)alkyl; R3 is cyano, hydroxyl, (C2-C4)alkenyl, (C1-C4)alkoxy or (C1-C4)alkoxycarbonyl; n is 0, 1 or 2; and m is 0, 1 or 2; and pharmaceutically acceptable salts thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.